Technology ID
TAB-3471

Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan

E-Numbers
E-022-2018-0
Lead Inventor
Singec, Ilyas (NCATS)
Co-Inventors
Chen, Yu (NCATS)
Simeonov, Anton (NCATS)
Applications
Research Materials
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NCATS
ICs
NCATS
This technology includes the use of the combination of the compounds Chroman-1 and Emricasan to achieve virtually 100% cell survival during human pluripotent stem cell passaging, cryopreservation/thawing, and differentiation in 2D and 3D cultures. Human pluripotent stem cells, including ESCs and iPSCs, are highly sensitive cells and undergo apoptosis during these routine procedures. A screening approach was used to identify the combination of the two compounds in this invention. The compounds allow dosing at a relatively low concentration, thus providing a cheaper iPSC growth media, stress-free environment, and minimization of off-target effects.
Commercial Applications
This invention will significantly improve quality assurance, characterization, and application of pluripotent stem cells in both pre-clinical and clinical settings.

Competitive Advantages
The combination of the compounds Chroman-1 and Emricasan permit a higher cell survival rate for pluripotent and differentiating cells compared to commonly used procedures.
Licensing Contact:
Vepa, Suryanarayana
sury.vepa@nih.gov